Expert Interview
Speaking With a Payor Expert on the Impact of a Closed Loop Distribution System with a Hub on the Entrance of a Generic in Ultra Orphan Diseases.
Ticker(s): CORT, TEVAInstitution: Schwarck Healthcare Reimbursement
- Experienced Healthcare Finance Consultant
- Specializes in new drug launch reimbursement support, hub access support and education, specialty drug reimbursement, and complex reimbursement issues
- Knowledgeable about market access, denials, appeals, pre-authorizations, and medical policy navigation.
Have you been part of any expensive treatments for orphan diseases going generic?
- Were any of those drugs distributed through a closed system/hub model?
How does a generic gain market share when the branded drug is distributed through a closed loop system?
Added By: joe_mccannHow important are physicians in converting patients to the generic drug?
Added By: joe_mccannAre there essential services the Hub provides to patients that must be replicated by the generic company?
Added By: joe_mccannAre generic companies like TEVA skilled at disrupting this type of market?
Added By: joe_mccannDoes this type of model limit the impact of multi source generics in the future, because those companies would also need to provide patient support services?
Added By: joe_mccannDoes the distribution system and hub provide significant value to the payor and patient outside of co-pay assistance?
Added By: joe_mccannDo payors think about the genericization drugs that have 1,500-5,000 patients in the entire US or is it such small $ that the few patients on the branded drug a given plan might have is irrelevant? Has this changed as more orphan diseases get expensive treatments approved.
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
